We have located links that may give you full text access.
Improving Clinical Diagnosis of COPD in Primary Care: Results of a Cluster-Randomized Controlled Study Utilizing a Screening Questionnaire With or Without a Handheld Spirometric Device Compared With Usual Care.
Chest 2012 October 2
SESSION TYPE: COPD: Diagnosis and EvaluationPRESENTED ON: Sunday, October 21, 2012 at 01:15 PM - 02:45 PMPURPOSE: COPD is often not diagnosed or diagnosed in later stages. Earlier diagnosis and intervention can lead to improved quality of life and physical functioning, fewer exacerbations, and lower mortality. The Screening, Evaluating and Assessing Rate CHanges of Diagnosing Respiratory Conditions in Primary Care (SEARCH) prospective cluster-randomized study assessed a symptom-based COPD population screener [COPD-PS] questionnaire with/without FEV1/FEV6 assessment by use of a handheld spirometric device [copd-6] to identify undiagnosed patients with COPD.METHODS: US primary care practices from seven states were randomized into three arms: Arm 1: COPD-PS plus copd-6 (if ≥5 score on the COPD-PS); Arm 2: COPD-PS alone; Arm 3: usual care. Sites received no additional training on COPD diagnosis and were not informed about the other arm interventions. Up to 55 consecutive subjects without a COPD diagnosis, aged ≥40 years, were recruited at each site. Data were abstracted from subjects' medical charts 8 weeks after study enrollment visit. The primary endpoint was the rate of new COPD diagnoses within 8 weeks after enrollment; the secondary endpoint was diagnostic practice pattern after screening at study enrollment visit (new COPD diagnosis, referral for spirometry, referral to pulmonologist, new respiratory medication prescription), in Arm 1 and Arm 2 vs Arm 3.RESULTS: Of 9704 subjects (Arm 1: 3201; Arm 2: 3296; Arm 3: 3207 subjects), mean age 60.2 yrs, 40.6% males, 82.9% Caucasian, 8770 had no prior diagnosis of COPD. The rate of new COPD diagnoses within 8 weeks of Visit 1 was statistically significantly higher in Arms 1 and 2 than Arm 3 (Arm 1: 1.16%, P=0.0021 (Odds Ratio [OR] 2.4); Arm 2: 1.07%, P=0.0060 (OR 2.2); Arm 3: 0.49%). Diagnostic practice patterns did not significantly differ between arms.CONCLUSIONS: Use of the COPD-PS and copd-6 resulted in higher rates of COPD diagnoses than usual care in this study, with combination screening having the highest yield.CLINICAL IMPLICATIONS: Use of screening tools in primary care could facilitate diagnosis of COPD in primary care.DISCLOSURE: Barbara Yawn: Consultant fee, speaker bureau, advisory committee, etc.: Barbara Yawn has received consultation fees from Boehringer-Ingelheim/Pfizer and research funding from Boehringer-Ingelheim/Pfizer, Novartis, GlaxoSmithKline and Merck related to chronic respiratory diseases.Karen Duvall: Consultant fee, speaker bureau, advisory committee, etc.: Compensation received from Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CTJohn Peabody: Consultant fee, speaker bureau, advisory committee, etc.: Compensation received from Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CTFrank Albers: Employee: Employee of Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CTAhmar Iqbal: Employee: Employee of Pfizer Inc, New York, NYStephen Koval: Employee: Employee of Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CTHeather Paden: Employee: Employee of Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CTWilliam Wadland: Consultant fee, speaker bureau, advisory committee, etc.: Compensation received from Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefield, CTNo Product/Research Disclosure InformationOlmsted Medical Center, Rochester, MN.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app